GSK Debt to Equity Ratio 2010-2022 | GSK
Current and historical debt to equity ratio values for GSK (GSK) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. GSK debt/equity for the three months ending December 31, 2022 was 1.69.
| GSK Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2022-12-31 |
$61.91B |
$12.49B |
4.96 |
| 2022-09-30 |
$60.77B |
$10.27B |
5.92 |
| 2022-06-30 |
$83.37B |
$28.43B |
2.93 |
| 2022-03-31 |
$89.98B |
$30.37B |
2.96 |
| 2021-12-31 |
$79.43B |
$29.35B |
2.71 |
| 2021-09-30 |
$78.52B |
$29.99B |
2.62 |
| 2021-06-30 |
$77.48B |
$30.16B |
2.57 |
| 2021-03-31 |
$78.70B |
$28.97B |
2.72 |
| 2020-12-31 |
$76.56B |
$26.72B |
2.87 |
| 2020-09-30 |
$77.90B |
$26.64B |
2.92 |
| 2020-06-30 |
$80.04B |
$24.99B |
3.20 |
| 2020-03-31 |
$82.35B |
$25.74B |
3.20 |
| 2019-12-31 |
$78.32B |
$23.44B |
3.34 |
| 2019-09-30 |
$80.38B |
$22.27B |
3.61 |
| 2019-06-30 |
$78.00B |
$3.82B |
20.45 |
| 2019-03-31 |
$76.84B |
$4.39B |
17.50 |
| 2018-12-31 |
$72.61B |
$4.90B |
14.81 |
| 2018-09-30 |
$71.51B |
$4.85B |
14.74 |
| 2018-06-30 |
$74.33B |
$4.11B |
18.07 |
| 2018-03-31 |
$73.16B |
$5.00B |
14.64 |
| 2017-12-31 |
$68.17B |
$4.50B |
15.16 |
| 2017-09-30 |
$70.64B |
$6.32B |
11.17 |
| 2017-06-30 |
$68.81B |
$5.66B |
12.16 |
| 2017-03-31 |
$66.45B |
$6.93B |
9.59 |
| 2016-12-31 |
$73.35B |
$6.73B |
10.90 |
| 2016-09-30 |
$71.95B |
$5.25B |
13.70 |
| 2016-06-30 |
$76.63B |
$6.06B |
12.64 |
| 2016-03-31 |
$68.69B |
$9.37B |
7.33 |
| 2015-12-31 |
$68.14B |
$13.57B |
5.02 |
| 2015-09-30 |
$67.90B |
$14.47B |
4.69 |
| 2015-06-30 |
$66.73B |
$16.16B |
4.13 |
| 2015-03-31 |
$70.63B |
$17.30B |
4.08 |
| 2014-12-31 |
$58.86B |
$8.14B |
7.24 |
| 2014-09-30 |
$57.74B |
$9.61B |
6.01 |
| 2014-06-30 |
$53.88B |
$11.51B |
4.68 |
| 2014-03-31 |
$53.42B |
$12.30B |
4.34 |
| 2013-12-31 |
$53.63B |
$12.22B |
4.39 |
| 2013-09-30 |
$53.18B |
$10.54B |
5.05 |
| 2013-06-30 |
$53.44B |
$11.17B |
4.78 |
| 2013-03-31 |
$54.81B |
$11.84B |
4.63 |
| 2012-12-31 |
$55.05B |
$10.70B |
5.15 |
| 2012-09-30 |
$52.81B |
$11.10B |
4.76 |
| 2012-06-30 |
$54.89B |
$12.35B |
4.45 |
| 2012-03-31 |
$49.06B |
$15.04B |
3.26 |
| 2011-12-31 |
$51.75B |
$14.16B |
3.65 |
| 2011-09-30 |
$53.49B |
$13.27B |
4.03 |
| 2011-06-30 |
$53.27B |
$15.40B |
3.46 |
| 2011-03-31 |
$52.34B |
$15.83B |
3.31 |
| 2010-12-31 |
$49.96B |
$15.07B |
3.32 |
| 2010-09-30 |
$49.65B |
$16.45B |
3.02 |
| 2010-06-30 |
$49.99B |
$14.24B |
3.51 |
| 2010-03-31 |
$51.73B |
$17.84B |
2.90 |
| 2009-12-31 |
$51.45B |
$15.67B |
3.28 |
| 2009-09-30 |
$52.81B |
$15.23B |
3.47 |
| 2009-06-30 |
$43.73B |
$11.95B |
3.66 |
| 2009-03-31 |
$44.73B |
$11.59B |
3.86 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$75.923B |
$36.279B |
|
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
|
